This article is more than 5 years old. Information may no longer be current.

Intracameral amphotericin B may speed fungal keratitis recovery

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Injecting intracameral amphotericin B may speed the disappearance of hypopyon and the improvement in vision in eyes with fungal keratitis, according to a study.

Kyung-Chul Yoon, MD, PhD, and colleagues studied the therapeutic efficacy of 10 [mu]g/0.1 mL of intracameral amphotericin B (ICAMB) in 14 patients with fungal keratitis. They compared these patients with 17 patients who received conventional treatment only.

The researchers found that the mean final logMAR visual acuity was 1.6 in ICAMB patients and 1.3 in controls. The time to disappearance of hypopyon averaged 9.4 days, time to epithelial defect closure averaged 19.8 days and time to final improvement averaged 26.6 days in ICAMB patients. In controls, time to hypopyon disappearance averaged 26.7 days, time to epithelial defect closure averaged 32.6 days and time to final improvement averaged 52.8 days, according to the study.

"At the last follow-up, treatment success was achieved in 92.9% of [ICAMB patients] and 82.4% of [controls]," the authors said.

The study is published in the August issue of Cornea.